The Association of the British Pharmaceutical Industry (ABPI), the industry body representing research-based drug companies, is urging the UK government to “move at pace” to deliver the clinical trial reforms it promised in two separate policy documents in 2021.
The proposed reforms are outlined in the government’s “Life Sciences Vision” and the policy paper on the “Future of UK Clinical Research Delivery